Serum Institute seeks Rs 30 billion from govt to boost AstraZeneca Covid vaccine output

Published On 2021-04-09 04:30 GMT   |   Update On 2021-04-09 04:30 GMT

New Delhi: The Serum Institute of India, the world's biggest vaccine manufacturer, has asked the government for a grant of 30 billion rupees ($402.97 million) to increase its capacity to make AstraZeneca's COVID-19 vaccine.It is seeking the money to ramp up monthly production to more than 100 million doses by the end of May, the government said in a statement on Wednesday, noting output...

Login or Register to read the full article

New Delhi: The Serum Institute of India, the world's biggest vaccine manufacturer, has asked the government for a grant of 30 billion rupees ($402.97 million) to increase its capacity to make AstraZeneca's COVID-19 vaccine.

It is seeking the money to ramp up monthly production to more than 100 million doses by the end of May, the government said in a statement on Wednesday, noting output was currently around 65-70 million doses a month.

The company is making vaccine doses for dozens of mainly poorer countries, though it has supplied Britain, Canada and Saudi Arabia due to AstraZeneca production issues elsewhere.

Read also: DCGI approves extension of shelf life of Covishield from 6 to 9 months: Report

About 90% of the 86 million doses India has administered since mid-January have come from the institute, with the rest accounted for by a domestic vaccine developed by Bharat Biotech, which is also struggling to boost output.

Some Indian states have complained of a vaccine shortage even though immunisations are currently limited to front-line workers and people aged over 45, or 400 million of India's 1.35 billion people.



Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News